Latest from Sarah Cannon

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.
 
Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).
Denise A. Yardley, MD, discusses the promise of CDK4/6 inhibitors in estrogen receptor–positive breast cancer, and the potential with immunotherapy agents.
Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.
Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.
Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with triple negative breast cancer (TNBC).
Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.
Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).
Publication Bottom Border
Border Publication
x